Search Page

The search found 3 results in 0.049 seconds.

Search results

  1. Biological DMARDs

    Biological DMARDs take the form of monoclonal antibodies (mAbs) and recombinant fusion proteins which modulate cytokine levels via mechanisms which inhibit T and B cell activation, or by directly inhibiting pro-inflammatory tumour necrosis factor alpha (TNFα). All cytokine modulators must be used under specialist supervision.

    Examples currently employed for anti-rheumatic therapy include:

    efaccena - 25/07/2016 - 2:22pm

  2. Drugs for SARS-CoV-2 infection (COVID-19)

    COVID-19 is the disease caused by infection by SARS-CoV-2 (severe acute respiratory syndrome virus 2), the airbourne, respiratory coronavirus that was first detected in China’s city of Wuhan in late 2019. The spread of this virus rapidly became a global pandemic that has resulted in millions of deaths. The pace of the subsequent response by the medical, pharmacology, scientific and pharmaceutical research communities has been unprecedented and delvered significant advances in both vaccinations and therapeutic interventions.

    efaccena - 05/04/2022 - 11:39am

  3. Disease-modifying anti-rheumatic drugs (DMARDs)

    Different types of arthritis (rheumatic disease) are treated with different drugs. The aim of the clinician is to prescribe drugs which improve symptoms and, where possible, slow or halt progress of the condition. As their name suggests, disease-modifying anti-rheumatic drugs (DMARDs) offer benefit via the latter mechanism. Full therapeutic response to DMARDs may take several months to become evident. Early intervention with DMARD therapy is recommended to control the signs and symptoms of rheumatic disease and to limit joint damage.

    efaccena - 22/07/2016 - 2:10pm